Ramkumar (Ram) Mandalam has served as the President & CEO and a Board Member and of Cellerant Therapeutics since 2008. Under his leadership, Cellerant has rapidly expanded from an early-stage to an advanced clinical-stage company developing a pipeline of candidates for treatment of heamatological malignancies. Prior to Cellerant, Dr. Mandalam led the development and manufacturing of cell-based therapies for treatment of degenerative diseases and cancer at Geron Corporation. Previously, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. He currently serves on the board of Cryoport, Inc. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.